Publications
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Sborov D, Suvannasankha A, Weisel K, Voorhees PM, Womersley L, Baron J, Piontek T, Lewis E, Opalinska J, Gupta I, Cohen AD. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021. PMID: 34314018
Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. PMID: 34312215
Letourneau J, Juarez-Hernandez F, Wald K, Ribeiro S, Wang A, McCulloch CE, Mok-Lin E, Dolezal M, Chien AJ, Cedars MI, Rosen M. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. Journal of assisted reproduction and genetics. 2021. PMID: 34312774
Brondfield S, Harmon D, Romero D, Tai J, Hsu G. Design-Based Bone Marrow Biopsy Training. Simulation in healthcare : journal of the Society for Simulation in Healthcare. 2021. PMID: 34319272
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic oncology. 2021. PMID: 34304981
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. PMID: 34292792
Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021. PMID: 34292324
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2021. PMID: 34778690
Mo CC, Jagannath S, Chari A, Nooka AK, Lonial S, Siegel D, Biran N, Gasparetto C, Bahlis NJ, Richardson P. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert review of hematology. 2021. PMID: 33985401
Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The Liver-Immunity Nexus and Cancer Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. PMID: 34285059
Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. PMID: 34285061
Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future oncology (London, England). 2021. PMID: 34278827
Chari A, Florendo E, Mancia IS, Cho H, Madduri D, Parekh S, Richter J, Dhadwal A, Thomas J, Jiang G, Lagana A, Bhalla S, Jagannath S. Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2021. PMID: 34404623
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood cancer discovery. 2021. PMID: 34514432
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood cancer discovery. 2021. PMID: 34514432